Newsfeeds - Spark Newswire

2 minute read

ConocoPhillips To Rally Over 30%? Here Are 10 Other Price Target Changes For Wednesday

Today, 8:46 AM

Barclays raised ConocoPhillips (NYSE: COP) price target from $135 to $151. Barclays analyst Jeanine Wai maintained an Overweight rating on the stock. ConocoPhillips shares fell 3.2% to close at $115.61 on Tuesday.

ABNB

1 minute read

Raymond James Maintains Outperform on Gossamer Bio, Lowers Price Target to $5

By Benzinga Newsdesk

Today, 8:46 AM

Raymond James analyst Steven Seedhouse maintains Gossamer Bio (NASDAQ:GOSS) with a Outperform and lowers the price target from $15 to $5.

GOSS

1 minute read

SVB Leerink Maintains Outperform on Gossamer Bio, Lowers Price Target to $10

By Benzinga Newsdesk

Today, 8:46 AM

SVB Leerink analyst Joseph Schwartz maintains Gossamer Bio (NASDAQ:GOSS) with a Outperform and lowers the price target from $15 to $10.

GOSS

3 minute read

Dow Dips Over 500 Points; Nasdaq Down 2.5%

By Lisa Levin

Today, 8:46 AM

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 2.5% on Tuesday.

BNED

1 minute read

Analyst Turns Bullish On Aerovate As Competitor Data Reinforce Lead Program Thesis

By Vandana Singh

Today, 8:46 AM

BTIG upgraded Aerovate Therapeutics Inc (NASDAQ:AVTE) from Neutral to Buy with a price target of $27. The analyst writes that to Aerovate’s…

AVTE

11 minute read

Options

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 8:46 AM

Tuesday's session saw 167 companies set new 52-week lows.

ACHL

3 minute read

S&P 500 Down Over 1%; Crude Oil Falls Sharply

By Lisa Levin

Today, 8:46 AM

U.S. stocks traded lower midway through trading, with the Dow Jones dropping around 250 points on Tuesday.

AZRE

2 minute read

Meta Platforms, Herbalife And Some Other Big Stocks Moving Lower On Tuesday

By Lisa Levin

Today, 8:46 AM

U.S. stocks traded lower, with the Dow Jones dropping over 200 points on Tuesday. Here are some big stocks recording losses in today’s session.

APP

1 minute read

Gossamer Bio Shares Plummet As Hypertension Trial Fall Short Of Expectation

By Vandana Singh

Today, 8:46 AM

Gossamer Bio Inc (NASDAQ:GOSS) announced topline results for the TORREY Phase 2 study of seralutinib in patients with pulmonary arterial hypertension…

GOSS

1 minute read

Gossamer Bio Announces Seralutinib Meets Primary Endpoint In Phase 2 TORREY Study In PAH

By Benzinga Newsdesk

Today, 8:46 AM

- Primary Endpoint, Change in PVR at Week 24, Met with P-Value of 0.0310 - - Secondary Endpoint, Change in 6MWD, Numerically Favored Seralutinib - - Statistically Significant Improvements Observed in NT-proBNP and ECHO

GOSS